Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Nr4a2 Transcription Factor in Hippocampal Synaptic Plasticity, Memory and Cognitive Dysfunction, A Perspective Review

  • Català-Solsona, Judit|||0000-0002-2927-9135
  • Miñano Molina, Alfredo Jesús|||0000-0002-7761-5682
  • Rodríguez Álvarez, José|||0000-0001-8582-8082
Long-lasting changes of synaptic efficacy are largely mediated by activity-induced gene transcription and are essential for neuronal plasticity and memory. In this scenario, transcription factors have emerged as pivotal players underlying synaptic plasticity and the modification of neural networks required for memory formation and consolidation. Hippocampal synaptic dysfunction is widely accepted to underlie the cognitive decline observed in some neurodegenerative disorders including Alzheimer's disease. Therefore, understanding the molecular pathways regulating gene expression profiles may help to identify new synaptic therapeutic targets. The nuclear receptor 4A subfamily (Nr4a) of transcription factors has been involved in a variety of physiological processes within the hippocampus, ranging from inflammation to neuroprotection. Recent studies have also pointed out a role for the activity-dependent nuclear receptor subfamily 4, group A, member 2 (Nr4a2/Nurr1) in hippocampal synaptic plasticity and cognitive functions, although the underlying molecular mechanisms are still poorly understood. In this review, we highlight the specific effects of Nr4a2 in hippocampal synaptic plasticity and memory formation and we discuss whether the dysregulation of this transcription factor could contribute to hippocampal synaptic dysfunction, altogether suggesting the possibility that Nr4a2 may emerge as a novel synaptic therapeutic target in brain pathologies associated to cognitive dysfunctions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Cancer metabolism in a snapshot, MRS(I)

  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
  • Candiota Silveira, Ana Paula|||0000-0002-1523-6505
  • Arús i Caraltó, Carles|||0000-0003-2510-2671
The contribution of MRS(I) to the in vivo evaluation of cancer-metabolism-derived metrics, mostly since 2016, is reviewed here. Increased carbon consumption by tumour cells, which are highly glycolytic, is now being sampled by 13C magnetic resonance spectroscopic imaging (MRSI) following the injection of hyperpolarized [1-13C] pyruvate (Pyr). Hot-spots of, mostly, increased lactate dehydrogenase activity or flow between Pyr and lactate (Lac) have been seen with cancer progression in prostate (preclinical and in humans), brain and pancreas (both preclinical) tumours. Therapy response is usually signalled by decreased Lac/Pyr 13C-labelled ratio with respect to untreated or non-responding tumour. For therapeutic agents inducing tumour hypoxia, the 13C-labelled Lac/bicarbonate ratio may be a better metric than the Lac/Pyr ratio. 31P MRSI may sample intracellular pH changes from brain tumours (acidification upon antiangiogenic treatment, basification at fast proliferation and relapse). The steady state tumour metabolome pattern is still in use for cancer evaluation. Metrics used for this range from quantification of single oncometabolites (such as 2-hydroxyglutarate in mutant IDH1 glial brain tumours) to selected metabolite ratios (such as total choline to N-acetylaspartate (plain ratio or CNI index)) or the whole 1H MRSI(I) pattern through pattern recognition analysis. These approaches have been applied to address different questions such as tumour subtype definition, following/predicting the response to therapy or defining better resection or radiosurgery limits.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Targeting the chemokine receptor CXCR4 for cancer therapies

  • Rueda, Ariana|||0000-0001-7588-9279
  • Serna, Naroa|||0000-0001-5682-8198
  • Mangues, Ramon|||0000-0003-2661-9525
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
The C-X-C chemokine receptor type 4 (CXCR4) has emerged as a key molecular biomarker for cancer therapies due to its critical role in tumor progression and metastases by displaying a stem cells phenotype. Its overexpression has been observed in more than 20 types of cancers, including solid tumors and hematological malignancies, and it is often associated with tumor aggressiveness and poor prognosis. Being initially recognized as a co-receptor involved in HIV infection, numerous CXCR4-targeting ligands and antagonists, including small molecules, peptides and biologics have been identified over the past decades. While only few of them have been used in the context of cancer therapies, recent biotechnological advancements using CXCR4 as a molecular target are showing significant potential to revolutionize future cancer therapies. Therefore, this review highlights the biotechnological innovations developed for cancer therapy and diagnosis by targeting the chemokine receptor CXCR4. It also discusses future perspectives on emerging therapeutic strategies, ranging from the use of small molecule inhibitors that block receptor signaling to cutting-edge nanocarriers designed for the targeted delivery of innovative drugs and proteins into cancer stem cells, aiming at cell-selective precision nanomedicines.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Cortical spreading depolarizations in stroke, Mechanisms, neuroprotective interventions, and monitoring techniques

  • Díaz Pérez, Andrea|||0009-0008-2215-6344
  • Alvarez de Eulate, Nerea|||0009-0009-9031-3388
  • Masvidal Codina, Eduard|||0000-0002-9579-8603
  • Illa, Xavi|||0000-0002-3212-1128
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
  • Guimerà Brunet, Anton|||0000-0003-1768-3293
  • Jiménez Altayó, Francesc|||0000-0002-9034-2041
  • Penas Pérez, Clara|||0000-0003-0554-3832
Cortical spreading depolarization (CSD) is a pathophysiological event critically implicated in ischemic stroke and other brain disorders. It consists of slowly propagating waves of massive neuronal and glial depolarization in cerebral gray matter, accompanied by spreading depression of cortical activity. CSD disrupts ion homeostasis, alters cerebral blood flow, and contributes to neuronal death in vulnerable tissue. This comprehensive review summarizes both classic and recent studies on CSD mechanisms and their role in brain damage progression after stroke. We also review potential neuroprotective strategies to mitigate CSD-induced damage and discuss available technologies for detecting CSD. Advancing our understanding of CSD mechanisms, combined with targeted neuroprotective strategies and improved monitoring techniques, holds promise for reducing stroke-related brain injury and guiding personalized recovery approaches.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Nanotoxin induces in situ pyroptosis to sensitize αPD1 to ablate metastases in microsattellite stable colorectal cancer

  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Otero-Mateo, Marc
  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Paez, David|||0000-0002-5596-6588
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ramon|||0000-0003-2661-9525
Nanomedicine has not generated anticancer immunotherapies because of insufficient targeted specificity, lack of immunity, and associated toxicity. We developed a T22-DITOX-H6 (TDX) nanotoxin to selectively release the diphtheria toxin in the cancer cells in immunosuppressed CXCR4-overexpressing (CXCR4 +) colorectal (CRC) models, inducing pyroptosis and anticancer effect. Microsatellite stable (MSS) CRC patients do not respond to current immunotherapy. Since pyroptosis is highly immunogenic, we treated with TDX immunocompetent CXCR4 + CT26 MSS metastatic CRC models to selectively deliver the toxin to induce in situ pyroptosis mediated by the activation of NLRP3, Caspase-1 GSDMD and IL-1β. In contrast to immunosuppressed, in situ pyroptosis by TDX in immunocompetent models trigger CD8 + T cell recruitment, activation and killing of cancer cells in tissues, mimicking the pyroptosis that the host induces to kill diphtheria-infected cells. The combination of TDX and αPD1 further increases CD8 + recruitment and perforin secretion, achieving a tissue-specific antimetastatic activity in mesentery, peritoneum, and lung, and especially in liver metastases, without systemic toxicity. This is the first time that a novel nanomedicine achieves local T cell activation and antimetastatic effect mediated by pyroptosis and immunogenic cell death, whereas the combination with αPD1 enhances T cell activation, reaching a synergistic response in MSS CRC models.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Delineating the factors and cellular mechanisms involved in the survival of cerebellar granule neurons

  • Xifro Collsamata, Francesc Xavier
  • Rodríguez Álvarez, José|||0000-0001-8582-8082
Cerebellar granule neurons (CGNs) constitute the most abundant neuronal population in the mammalian brain. Their postnatal generation and the feasibility to induce their apoptotic death in vitro make them an excellent model to study the effect of several neurotransmitters and neurotrophins. Here, we first review which factors are involved in the generation and proliferation of CGNs in the external granule layer (EGL) and in the regulation of their differentiation and migration to internal granule layer (IGL). Special attention was given to the role of several neurotrophins and the NMDA subtype of glutamate receptor. Then, using the paradigm of potassium deprivation in cultured CGNs, we address several extracellular factors that promote the survival of CGNs, with particular emphasis on the cellular mechanisms. The role of specific protein kinases leading to the regulation of transcription factors and recent data involving the small G protein family is also discussed. Finally, the participation of some members of Bcl-2 family and the inhibition of mitochondria-related apoptotic pathway is also considered. Altogether, these studies evidence that CGNs are a key model to understand the development and the survival of neuronal populations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Schwann Cell Role in Selectivity of Nerve Regeneration

  • Bolívar Martín, Sara|||0000-0003-2966-6845
  • Navarro, Xavier|||0000-0001-9849-902X
  • Udina i Bonet, Esther|||0000-0003-1954-8562
Peripheral nerve injuries result in the loss of the motor, sensory and autonomic functions of the denervated segments of the body. Neurons can regenerate after peripheral axotomy, but inaccuracy in reinnervation causes a permanent loss of function that impairs complete recovery. Thus, understanding how regenerating axons respond to their environment and direct their growth is essential to improve the functional outcome of patients with nerve lesions. Schwann cells (SCs) play a crucial role in the regeneration process, but little is known about their contribution to specific reinnervation. Here, we review the mechanisms by which SCs can differentially influence the regeneration of motor and sensory axons. Mature SCs express modality-specific phenotypes that have been associated with the promotion of selective regeneration. These include molecular markers, such as L2/HNK-1 carbohydrate, which is differentially expressed in motor and sensory SCs, or the neurotrophic profile after denervation, which differs remarkably between SC modalities. Other important factors include several molecules implicated in axon-SC interaction. This cell-cell communication through adhesion (e.g., polysialic acid) and inhibitory molecules (e.g., MAG) contributes to guiding growing axons to their targets. As many of these factors can be modulated, further research will allow the design of new strategies to improve functional recovery after peripheral nerve injuries.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Tejero Laguna, Eudald|||0000-0002-7536-4322
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Surralles, Jordi|||0000-0002-4041-7519
Cancer is a complex disease resulting from the accumulation of genetic dysfunctions. Tumor heterogeneity causes the molecular variety that divergently controls responses to chemotherapy, leading to the recurrent problem of cancer reappearance. For many decades, efforts have focused on identifying essential tumoral genes and cancer driver mutations. More recently, prompted by the clinical success of the synthetic lethality (SL)-based therapy of the PARP inhibitors in homologous recombinant deficient tumors, scientists have centered their novel research on SL interactions (SLI). The state of the art to find new genetic interactions are currently large-scale forward genetic CRISPR screens. CRISPR technology has rapidly evolved to be a common tool in the vast majority of laboratories, as tools to implement CRISPR screen protocols are available to all researchers. Taking advantage of SLI, combinatorial therapies have become the ultimate model to treat cancer with lower toxicity, and therefore better efficiency. This review explores the CRISPR screen methodology, integrates the up-to-date published findings on CRISPR screens in the cancer field and proposes future directions to uncover cancer regulation and individual responses to chemotherapy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Experimental Models for Aging and their Potential for Novel Drug Discovery

  • Folch, Jaume
  • Busquets, Oriol|||0000-0002-1372-9699
  • Ettcheto, Miren|||0000-0002-4301-7297
  • Sánchez-López, Elena|||0000-0003-2571-108X
  • Pallàs, Mercè|||0000-0003-3095-4254
  • Beas-Zarate, Carlos
  • Marin, Miguel
  • Casadesus, Gemma|||0000-0002-5206-5637
  • Olloquequi, Jordi|||0000-0002-6492-2739
  • Auladell, Carme|||0000-0001-8345-1859
  • Camins, Antoni|||0000-0002-1229-5956
An interesting area of scientific research is the development of potential antiaging drugs. In order to pursue this goal, it is necessary to gather the specific knowledge about the adequate preclinical models that are available to evaluate the beneficial effects of new potential drugs. This review is focused on invertebrate and vertebrate preclinical models used to evaluate the efficacy of antiaging compounds, with the objective to extend life span and health span. Research and online content related to aging, antiaging drugs, experimental aging models is reviewed. Moreover, in this review, the main experimental preclinical models of organisms that have contributed to the research in the pharmacol-ogy of lifespan extension and the understanding of the aging process are discussed. Dietary restriction (DR) constitutes a common experimental process to extend life span in all organisms. Besides, classical antiaging drugs such as resveratrol, rapamycin and metformin denominated as DR mimetics are also discussed. Likewise, the main therapeutic targets of these drugs include sirtuins, IGF-1, and mTOR, all of them being modulated by DR. Advances in molecular biology have uncovered the potential molecular pathways involved in the aging process. Due to their characteristics, invertebrate models are mainly used for drug screening. The National Institute on Aging (NIA) developed the Interventions Testing Program (ITP). At the pre-clinical level, the ITP uses Heterogeneous mouse model (HET) which is probably the most suitable rodent model to study potential drugs against aging prevention. The accelerated-senescence mouse P8 is also a mammalian rodent model for aging research. However, when evaluating the effect of drugs on a preclinical level, the evaluation must be done in non-human primates since it is the mammalian specie closest to humans. Research is needed to investigate the impact of new potential drugs for the increase of human quality of.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Epigenetic Modifications Associated to Neuroinflammation and Neuropathic Pain After Neural Trauma

  • Penas Pérez, Clara|||0000-0003-0554-3832
  • Navarro, X. (Xavier)|||0000-0001-9849-902X
Accumulating evidence suggests that epigenetic alterations lie behind the induction and maintenance of neuropathic pain. Neuropathic pain is usually a chronic condition caused by a lesion, or pathological change, within the nervous system. Neuropathic pain appears frequently after nerve and spinal cord injuries or diseases, producing a debilitation of the patient and a decrease of the quality of life. At the cellular level, neuropathic pain is the result of neuronal plasticity shaped by an increase in the sensitivity and excitability of sensory neurons of the central and peripheral nervous system. One of the mechanisms thought to contribute to hyperexcitability and therefore to the ontogeny of neuropathic pain is the altered expression, trafficking, and functioning of receptors and ion channels expressed by primary sensory neurons. Besides, neuronal and glial cells, such as microglia and astrocytes, together with blood borne macrophages, play a critical role in the induction and maintenance of neuropathic pain by releasing powerful neuromodulators such as pro-inflammatory cytokines and chemokines, which enhance neuronal excitability. Altered gene expression of neuronal receptors, ion channels, and pro-inflammatory cytokines and chemokines, have been associated to epigenetic adaptations of the injured tissue. Within this review, we discuss the involvement of these epigenetic changes, including histone modifications, DNA methylation, non-coding RNAs, and alteration of chromatin modifiers, that have been shown to trigger modification of nociception after neural lesions. In particular, the function on these processes of EZH2, JMJD3, MeCP2, several histone deacetylases (HDACs) and histone acetyl transferases (HATs), G9a, DNMT, REST and diverse non-coding RNAs, are described. Despite the effort on developing new therapies, current treatments have only produced limited relief of this pain in a portion of patients. Thus, the present review aims to contribute to find novel targets for chronic neuropathic pain treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis, A Systematic Review and a Network Meta-Analysis

  • Tejada, Sofia|||0000-0002-2000-6587
  • Ramírez-Estrada, Sergio
  • Forero, Carlos G.|||0000-0002-5245-0076
  • Gallego, Miguel|||0000-0002-8882-4033
  • Soriano, Joan B.|||0000-0001-9740-2994
  • Cardinal-Fernández, Pablo A.|||0000-0002-4459-8919
  • Ehrmann, Stephan
  • Rello, Jordi|||0000-0003-0676-6210
It remains unknown whether the type of aerosol generating device is affecting efficacy and safety among non-cystic fibrosis bronchiectasis (NCFB) adults. The proposal of this network meta-analysis (NMA) is to evaluate effectiveness and safety of inhaled antibiotics administered via dry powder inhaler (DPI) and via nebulizers (SVN) among adult patients with NCFB. Inclusion criteria were randomized-controlled trials, adults (≥18 years) with NCFB, and inhaled antibiotics administered via DPI as intervention. Search strategy was performed in PubMed, Web of Science, and Cochrane Library from 2000 to 2019. Sixteen trials (2870 patients) were included. Three trials (all ciprofloxacin) used DPIs and thirteen used SVN (three ciprofloxacin). Both DPI and SVN devices achieved similar safety outcomes (adverse events, antibiotic discontinuation, severe adverse events, and bronchospasm). Administration of ciprofloxacin via DPI significantly improved time to first exacerbation (87 days, 95% CI 34.3-139.7) and quality of life (MD -7.52; 95% CI -13.06 to -1.98) when compared with via SVN. No other significant differences were documented in clinical efficacy (at least one exacerbation, FEV% predicted) and microbiologic response (bacterial eradication, emergence of new potential pathogens, and emergence of antimicrobial resistance) when comparing devices. Our NMA documented that time to first exacerbation and quality of life, were more favorable for DPIs. Decisions on the choice of devices should incorporate these findings plus other criteria, such as simplicity, costs or maintenance requirements.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Advances in the Use of Deep Learning for the Analysis of Magnetic Resonance Image in Neuro-Oncology

  • Pitarch, Carla|||0000-0002-6015-244X
  • Ungan, Gulnur Semahat|||0000-0002-5436-4665
  • Julià Sapé, Ma. Margarita|||0000-0002-3316-9027
  • Vellido, Alfredo|||0000-0002-9843-1911
Machine Learning is entering a phase of maturity, but its medical applications still lag behind in terms of practical use. The field of oncological radiology (and neuro-oncology in particular) is at the forefront of these developments, now boosted by the success of Deep-Learning methods for the analysis of medical images. This paper reviews in detail some of the most recent advances in the use of Deep Learning in this field, from the broader topic of the development of Machine-Learning-based analytical pipelines to specific instantiations of the use of Deep Learning in neuro-oncology; the latter including its use in the groundbreaking field of ultra-low field magnetic resonance imaging.